House Bill 2075, known as the "Helping Open Pathways to Effective (HOPE) Treatment Act," aims to facilitate clinical trials for ibogaine, a psychoactive compound with potential therapeutic benefits for various mental health and neurological conditions. The bill establishes a new chapter in the Tennessee Code Annotated, specifically under Title 33, which outlines the creation of cohorts that include drug developers, research institutions, and hospitals to conduct drug development clinical trials for ibogaine. The bill mandates that these cohorts submit proposals for funding to the Department of Mental Health and Substance Abuse Services, detailing their plans for obtaining FDA approval, trial design, and patient care protocols.

Additionally, the bill includes provisions for the establishment of a Tennessee mental health innovation fund, which will receive a portion of the revenue generated from intellectual property rights related to the clinical trials. This fund is intended to support training and best practices for behavioral health providers working with patients who have undergone ibogaine therapy. The act will only apply if ibogaine is approved by the FDA for medical use, and it is set to take effect on July 1, 2026.